Compare Novartis AG (NVS) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Novartis AG trades at $142.04 (market cap $274.00B), while Direxion Daily TSLA Bull 2X Shares trades at $10.26 (market cap $4.08B). The key difference: Novartis AG is far larger — about 67.2× Direxion Daily TSLA Bull 2X Shares's market cap, and Novartis AG pays a 3.31% dividend while Direxion Daily TSLA Bull 2X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Direxion Daily TSLA Bull 2X Shares for 15 Days on average.
| NVS | TSLL | |
|---|---|---|
Market Cap | $274.00B | $4.08B |
Volume | 1,852,137 | 46,206,477 |
Sector | Health | Leveraged / Inverse |
52-Week High | $168.62 | $23.03 |
52-Week Low | $121.80 | $6.74 |
Typical Hold Time | 82 Days | 15 Days |
Enterprise Value | $315.32B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $10.15, down 1.55% on the day. The overall technical signal is bullish, supported by moving averages, while oscillators are neutral. Recent news highlights its sensitivity to Tesla's stock movements, with a notable rally tied to Cybercab hype. As a leveraged ETF, it aims to deliver twice Tesla's daily returns, amplifying both gains and losses.
The outlook for TSLL is directly tied to Tesla's performance, offering high-risk, high-reward exposure. Key risks include volatility decay from daily rebalancing and dependence on Tesla-specific events. Investors seeking amplified Tesla returns may find opportunity, but must be wary of the inherent leverage risks in a volatile stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
